Article information
Full text is only aviable in PDF
Bibliografía
[1.]
G. Peces-Barba, J.A. Barberà, A. Agustí, C. Casanova, A. Casas, J.L. Izquierdo.
Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC.
Arch Bronconeumol, 44 (2008), pp. 271-281
[2.]
J.L. Izquierdo.
The burden of COPD in Spain: Results from the confronting survey.
Respir Med, 97 (2003), pp. S61-S69
[3.]
P. Enright.
Does screening for COPD by primary care physicians have the potential to cause more harm than good?.
Chest, 129 (2006), pp. 833-834
[4.]
A. Punturieri, T.L. Croxton, G.G. Weinmann, J.P. Kiley.
Chronic obstructive pulmonary disease: A view from the NHLBI.
Am J Respir Crit Care Med, 178 (2008), pp. 441-443
[5.]
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Disponible en: www.goldcopd.com
[6.]
M. Pistolesi, G. Camiciottoli, M. Paoletti, C. Marmai, F. Lavorini, E. Meoni, et al.
Identification of a predominant COPD phenotype in clinical practice.
Respir Med, 102 (2008), pp. 367-376
[7.]
P.J. Barnes.
New therapies for chronic obstructive pulmonary disease.
Med Princ Pract, 19 (2010), pp. 330-338
[8.]
A. Hatzelmann, E.J. Morcillo, G. Lungarella, S. Adnot, S. Sanjar, R. Beume, et al.
The preclinical pharmacology of roflumilast: A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Pulm Pharmacol Ther, 23 (2010), pp. 235-256
[9.]
P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, F.J. Martínez.
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Lancet, 374 (2009), pp. 685-694
[10.]
L.M. Fabbri, P. Calverley, J.L. Izquierdo, D. Bundschuh, M. Brose, F.J. Martínez, et al.
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Lancet, 374 (2009), pp. 695-703
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
